Trastuzumab emtansine biosimilar(Hetero Biopharma)

N/A

Report date: 2022/01/29 10:33:52

Base Information

Drug NameTrastuzumab emtansine biosimilar(Hetero Biopharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAnti-HER2Tubulin inhibitors

TargetsReceptor protein-tyrosine kinase erbB-2Tubulin

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHetero Drugs Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHetero Drugs Ltd

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A